- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05927376
Mediterranean-style Dietary Pattern (MDP), Mood and Anxiety (MediMood)
MediMood: A Randomised Controlled Trial Investigating the Acute Impact of a Plant Based Mediterranean-style Dietary Pattern (MDP) on Mood, Anxiety and Cognition in UK Adults With Mild to Moderate Mental Health Complaints
Observational studies and a limited numbers of RCTs have observed that habitual Mediterranean-style dietary pattern (MDP) consumption is associated with improved mental health and cognition. Yet, its efficacy in a short-term has not been studied in well-controlled intervention settings.
MediMood is a cross-over RCT aiming to test whether a MDP can affect mood and anxiety following a meal (postprandial) and over 5-days in adults over 18 years with mild to moderate mental health problems relative to a Western diet (WD).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Depression, anxiety and age-related cognitive decline are leading global public health problems. A plant-based Mediterranean-style dietary pattern (MDP) includes olive oil as the main source of fat, fresh fruits, vegetables, seafood, legumes and nuts and a low consumption of red and processed meat, confectionary, and high-sugar drinks. A MDP promotes both physical and mental wellbeing and brain function. However, most studies to date have examined the impact of a MDP on health over months or years. As several underpinning biological mechanisms are likely to be responsive within hours or days, examining the short-term effect of a MDP on mental health outcomes is important. The overall goal of the present study is to understand the effects of a MDP on acute/sub-chronic brain health and its underpinning mechanisms.
MediMood is a randomised cross-over efficacy trial. Participants will be assigned to an isocaloric MDP and a Western diet (WD) for 5-days in a random order with a 4-week wash-out period. All foods, meal plans and detailed dietary instructions will be provided. In addition to the primary outcome measures (mood and anxiety), the impact of intervention on cognitive performance, sleep, cerebral blood flow (MRI) and a selection of biomarkers of brain function will be measured in biological samples over five days.
As low mood, anxiety and stress disorders affect daily functioning and reduce the quality of life significantly for many, the investigators believe the findings will have wide public health application.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Anne Marie M Minihane, PhD
- Phone Number: 01603592389
- Email: a.minihane@uea.ac.uk
Study Contact Backup
- Name: Latife Esgunoglu, MSc
- Phone Number: +441603592389
- Email: l.esgunoglu@uea.ac.uk
Study Locations
-
-
Norfolk
-
Norwich, Norfolk, United Kingdom, NR4 7UQ
- Recruiting
- University of East Anglia
-
Principal Investigator:
- Anne Marie Minihane, PhD
-
Contact:
- Latife Esgunoglu, MSc
- Phone Number: +441603592389
- Email: l.esgunoglu@uea.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female, aged 18 or above
- Is willing and able to comply with all study procedures, including changes in diets
- Has access to and able to use the internet/computer/tablet device
- Mild to moderate level of anxiety and/or depression symptoms, assessed by Generalised Anxiety disorder (GAD-7) score and Patient Health Questionnaire (PHQ-9), scores 5 to 14 on both questionnaires
- A habitual MEDAS score of ≤ 7/14
- To be fluent in English
Exclusion Criteria:
- MEDAS score >7
- Vegan/vegetarian
- Allergies to one of the study components i.e. nuts, fish
- On antidepressant or antianxiety medication where dosage is likely to change over the next 3 month
- Factors precluding MRI scanning such as suffers from claustrophobia or has metal implants
- Not fluent in English
- Not agreement for the study team to contact the participants general practitioner about trial participation and screening results
- Not prepared to make changes to the diet for 10 days (2 x 5 day periods)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mediterranean-style dietary pattern
A Mediterranean-style diet (as a whole diet, no supplements)
|
All foods, meal plans and instructions provided.
|
Active Comparator: Western-style dietary pattern
A Western-style diet (as a whole diet, no supplements)
|
All foods, meal plans and instructions provided.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mood
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on Established by the Bond-Lader visual analogue scale (includes 16 items each having day 1), 24-hours (morning of day 2), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Established by the Bond-Lader visual analogue scale (includes 16 items each having antonyms on two ends, on a scale of 1 to 100, 50 being the neutral point)
|
Baseline (morning of day 1), Postprandial (after lunch on Established by the Bond-Lader visual analogue scale (includes 16 items each having day 1), 24-hours (morning of day 2), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Change in anxiety
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), 24-hours (morning of day 2), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Established by the Profile of Mood States (includes 65 items on a 5 point Likert scale)
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), 24-hours (morning of day 2), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognitive performance
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Established by a neuropsychological test battery (https://neuropsychology.online) which assesses the following measures; attention, motor function, executive function, episodic memory, impulse control, visuospatial function
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Cerebral blood flow
Time Frame: Postprandial day 1
|
Measured using MRI
|
Postprandial day 1
|
Change in blood pressure
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Measurements of brachial artery blood pressure (both diastolic and systolic pressure)
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Change in gut microbiota speciation
Time Frame: Baseline (morning of day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Faecal samples will be analysed for the gut microflora using 16sRNA sequencing.
|
Baseline (morning of day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Change in plasma short chain fatty acids (SCFA)
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Acetate, propionate and butyrate
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Change in untargeted metabolomics
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Analysed through faecal samples using 1H-NMR-based untargeted metabolomics approach.
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Habitual sleep quality profile assessed by the Pittsburgh Sleep Quality Index
Time Frame: Baseline (morning of day 1)
|
The Pittsburgh Sleep Quality Index is a 10-items validated questionnaire, which is based on 'the last month'.
It will be used to establish usual sleep habits (before the interventions) and to identify sleep disturbances if there is any.
|
Baseline (morning of day 1)
|
Change in subjective sleep quantity
Time Frame: Each morning, days 1-6
|
Assessed using the Karolinska Sleep Diary (KSD).
The KSD is a series of questions, with 5 possible tick box options, which characterise the efficiency and the duration of last night's sleep.
|
Each morning, days 1-6
|
Change in subjective sleep quality
Time Frame: Each morning, days 1-6
|
Assessed using the Karolinska Sleepiness Scale (KSS).
The KSS is a single item, 9-point scale, assessing the sleepiness level at a particular time of day.
|
Each morning, days 1-6
|
Change in objective sleep quality
Time Frame: Each morning, days 1-6
|
Assessed using the MotionWatch 8.
The MotionWatch 8 is a medical-grade actigraphy watch which can be used to monitor sleep, circadian rhythm and physical activity.
Its software (The Motion Ware) will provide two objective measures of sleep quality, namely sleep efficiency and sleep fragmentation.
|
Each morning, days 1-6
|
APOE4 genotype status
Time Frame: Baseline (day 1)
|
Assessed through DNA genotyping
|
Baseline (day 1)
|
Participants subjective overview of the intervention
Time Frame: Upon completion of 5 full days
|
Assessed through a non-validated single question
|
Upon completion of 5 full days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in dietary behaviour
Time Frame: Screening and 3 months upon the completion
|
Through the Mediterranean Diet Adherence Screener (14 items food questionnaire, MEDAS) questionnaire, with a minimum score of 0 and a maximum of 14.
A higher score indicates a higher diet quality which is a better outcome
|
Screening and 3 months upon the completion
|
Change in plasma insulin
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Measured using ELISA
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Change in plasma glucose
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Measured by autoanalyser
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Change in plasma triglycerides
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Measured by autoanalyser
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Change in plasma cortisol
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Measured by autoanalyser
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Change in plasma brain derived neurotropic factor
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Measured by ELISA
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Change in plasma serotonin
Time Frame: Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Measured by ELISA
|
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anne Marie Minihane, University of East Anglia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R211670
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression, Anxiety
-
University Hospital, Strasbourg, FranceCompletedAnxiety Depression DisorderFrance
-
ViomeRecruitingDepression | Anxiety Disorders | Anxiety | Mental Health Disorder | Anxiety Depression | Anxiety State | Mental Health | Depression, Anxiety | Mental Health IssueUnited States
-
3-C Institute for Social DevelopmentUniversity of Miami; Stony Brook UniversityCompletedDepression | Anxiety | Depression, Anxiety | Depression in AdolescenceUnited States
-
University Hospital, Strasbourg, FranceRecruitingDepression Anxiety DisorderFrance
-
UCLH/UCL Joint Research OfficeMedical Research Council; Camden and Islington NHS Trust; Central and North West...RecruitingAnxiety Disorders | Anxiety | Anxiety Depression | CBT | Anxiety Disorders and Symptoms | Anxiety Generalized | Generalised Anxiety Disorder | Anxiety Disorder; Mixed With Depression (Mild) | Anxiety Disorder GeneralizedUnited Kingdom
-
University of Southern CaliforniaCompletedAnxiety | Depression, Anxiety | Depression Mild | Attention Concentration DifficultyUnited States
-
NeuroGlove LLCRecruitingDepression | Anxiety | Anxiety Depression | Depression, AnxietyUnited States
-
University of Wisconsin, MadisonNot yet recruiting
-
Northern Jiangsu People's HospitalRecruitingDepression, AnxietyChina
-
University of South FloridaNational Institute of Mental Health (NIMH)RecruitingDepression | Anxiety | Depression/AnxietyUnited States
Clinical Trials on Mediterranean diet
-
Purdue UniversityMushroom CouncilCompleted
-
University of California, IrvineCompletedPolycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloproliferative Disorder | Myeloproliferative SyndromeUnited States
-
Gangnam Severance HospitalUnknown
-
Federico II UniversityCompletedMediterranean Diet | Neuroendocrine Tumours (NETs)Italy
-
Azienda Ospedaliera Specializzata in Gastroenterologia...Completed
-
University of California, DavisCompletedInflammation | Diet Modification | HDLUnited States
-
michal rollUnknown
-
University of Campania "Luigi Vanvitelli"CompletedType 2 Diabetes MellitusItaly
-
Chih-Ping ChungNational Yang Ming Chiao Tung UniversityRecruiting
-
Azienda Ospedaliero-Universitaria CareggiCompleted